Official EU label nameGlossary entry 27447
SPIRONOLACTONE
This record confirms an official common ingredient name for EU cosmetic product labelling. It does not by itself confirm that the substance is permitted, unrestricted or safe.
Global evidence snapshot
The resolved identity has matching regulatory evidence in 9 of 13 indexed market datasets: 9 country records and 0 EU Annex records. Every result and evidence gap is listed below.
Markets checked
13
Markets with evidence
9
Evidence gaps
4
Resolved identifiers
2
Resolved substance identity
CAS:52-01-7
EC:200-133-6
Ingredient index records:
SPIRONOLACTONE
Cosmetic functions: NOT REPORTED
17-alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7-alpha-mercapto- 3-oxo-, gamma-lactone acetate
Inventory restriction note: II/4
7 matched or reported names
SPIRONOLACTONESpironolactone (INN)Spironolactone螺内酯 — Spironolactone （INN） （CAS No. 52-01-7）스피로노락톤Espironolactona*Spironolactone (*) (CAS No. 52-01-7)
Regulatory evidence in all 13 markets
Open each matched record for its scope, concentration, conditions, warnings and official source version.
Swipe or scroll horizontally to see dataset coverage and next actions.
| Market | Result | Records | Dataset | Meaning / next action |
|---|---|---|---|---|
| European Union EU | No local match | 0 | Complete annex dataset Regulation (EC) 1223/2009 consolidated to 1 May 2026 | No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review. |
| Great Britain GB | Prohibited | 1Open record 1 | Complete consolidated annex dataset GB retained Regulation 1223/2009 schedules, effective 15 August 2026 | Review every linked record and exact conditions. |
| Canada CA | Prohibited | 1Open record 1 | Complete Hotlist snapshot Health Canada Cosmetic Ingredient Hotlist, 13 August 2025 | Review every linked record and exact conditions. |
| New Zealand NZ | Prohibited | 1Open record 1 | Complete schedules dataset Cosmetic Products Group Standard schedules effective 1 January 2026 | Review every linked record and exact conditions. |
| ASEAN ASEAN | Prohibited | 1Open record 1 | Complete regional annex dataset ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026 | Review every linked record and exact conditions. |
| China CN | Prohibited | 1Open record 1 | Complete prohibited catalogues plus official-source workflow NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025 | Review every linked record and exact conditions. |
| Japan JP | No local match | 0 | Complete Standards appendices dataset MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot | The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion. |
| South Korea KR | Prohibited | 1Open record 1 | Complete current appendix dataset MFDS Notice 2026-19, effective 18 March 2026 | Review every linked record and exact conditions. |
| United States US | No local match | 0 | Complete enumerated federal ingredient rules eCFR Title 21 issue date 27 August 2026 | FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety. |
| Australia AU | No local match | 0 | Complete cosmetic-relevant Poisons Standard subset plus official workflow Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 | An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction. |
| Brazil BR | Prohibited | 1Open record 1 | Complete prohibited dataset plus current restricted-list workflow ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026 | Review every linked record and exact conditions. |
| India IN | Prohibited | 1Open record 1 | Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4 Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022) | Review every linked record and exact conditions. |
| Saudi Arabia SA | Prohibited | 1Open record 1 | Complete official list index SFDA live prohibited/restricted lists, snapshot 30 August 2026 | Review every linked record and exact conditions. |
No market rows match this filter.
Matching market records and conditions
Canada
Health Canada Cosmetic Ingredient Hotlist, 13 August 2025New Zealand
Cosmetic Products Group Standard schedules effective 1 January 2026ASEAN
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026China
NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025South Korea
MFDS Notice 2026-19, effective 18 March 2026Brazil
ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026India
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)Saudi Arabia
SFDA live prohibited/restricted lists, snapshot 30 August 2026Chemical identity and properties
CAS 52-01-7PubChem CID 5833
Spironolactone
Spironolactone is a steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7. It has a role as a diuretic, an antihypertensive agent, a xenobiotic, an aldosterone antagonist and an environmental contaminant. It is a steroid lactone, an oxaspiro compound, a 3-oxo-Delta(4) steroid and a thioester. — ChEBI
- IUPAC name
- S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
- Molecular formula
- C24H32O4S
- Molecular weight
- 416.6 g/mol
- Exact mass
- 416.20213067 Da
- XLogP3
- 2.9
- Topological polar surface area
- 85.7 Ų
- Hydrogen-bond donors
- 0
- Hydrogen-bond acceptors
- 5
- Covalent units
- 1
- Defined stereocentres
- 7
Also known as
AldactoneVerospironeSpirolactoneSpiresisUractoneXenalonspironolattoneEspironolactona
16 more reported names
SpironolactonumAbbolactoneDiatensecLaractoneSC 9420SC-9420Spironolactone cevaCarospirSpireticNSC-15039927O7W4T232CHEBI:9241VeroshpironSC94203-(3-Keto-7-alpha-acetylthio-17-beta-hydroxy-4-androsten-17-alpha-yl)propionic acid lactone17alpha-Pregn-4-ene-21-carboxylic acid, 17-hydroxy-7alpha-mercapto-3-oxo-, gamma-lactone, acetate
External database identifiers
- ChEBI:CHEBI:9241
- ChEMBL:CHEMBL1393
- EPA DTXSID:DTXSID6034186
- PubMed:31065620
- PubMed:28024992
- PubMed:23116347
- PubMed:23105506
- PubMed:23077889
- PubMed:23077888
- PubMed:23077601
- PubMed:23074496
- PubMed:23074464
- PubMed:23060371
- PubMed:23035601
- PubMed:23031616
Retrieved from NIH PubChem on 2026-08-31 by checksum-valid CAS matching. Chemical properties do not replace the regulatory decision on this page.
Additional authoritative substance research
Each link searches that source for this identity. A link is a research route, not a claim that the source holds an exact record. What each source is, and its legal weight
Take this record further
Official source and scope
Imported from Commission Implementing Decision (EU) 2025/1175 (dataset version EU 2025/1175). The glossary supplies common ingredient names for the ingredient list required by Article 19(1)(g); it is not an approval or safety list.
Open official Decision